Chlorine-coordinated iron single-atom nanozymes for amplified ferroptosis in triple-negative breast cancer therapy
Triple-negative breast cancer (TNBC) represents an aggressive breast cancer subtype with limited therapeutic options and poor prognosis. Although single-atom nanozymes (SAzymes) show promise in cancer therapy, their ferroptosis-inducing capability remains limited. Herein, we present a rationally designed iron-based SAzyme with axial chlorine coordination (FeN<sub>4</sub>Cl) that integrates catalytic and metabolic functions to enhance ferroptosis in TNBC. The engineered Fe-Cl coordination strategically modulates the d-band center relative to the Fermi level, resulting in significantly enhanced peroxidase-like activity (2.0-fold increase) and glutathione oxidase-like activity (3.2-fold increase) activities compared to conventional FeN<sub>4</sub> structures. Importantly, this electronic modulation triggers NCOA4-mediated ferritinophagy, establishing an autonomous iron supply mechanism that elevates intracellular labile Fe<sup>2+</sup> levels. The synergistic disruption of redox homeostasis coupled with amplified Fenton reactions creates a feedback loop that induces cell death. Encapsulation within red blood cell membranes (FeN<sub>4</sub>Cl/RBC) improves biocompatibility and tumor targeting. Both in vitro and in vivo studies demonstrate that FeN<sub>4</sub>Cl/RBC substantially suppresses tumor growth through effective ferroptosis, presenting a promising approach for developing clinically relevant nanozyme-based therapeutics.
Authors
- Fenghua Xu (ORCID: https://orcid.org/0000-0002-3610-0690)
- Xingsheng Hu
- Mingming Yin
- Huijuan Wang
- Jie Ouyang
- Yongping Liu
- Xiong Wang
- Yi Chen
- Shuang-Feng Yin
Institutions
- Central South University of Forestry and Technology (CN)
- Central South University (CN)
- Hunan University of Traditional Chinese Medicine (CN)
- Ministry of Education (SA)
Publication Details
- Journal
- Journal of Nanobiotechnology
- Published
- 2026-02-24
- DOI
- https://doi.org/10.1186/s12951-026-04096-9
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00